Alzheon CEO, Martin Tolar, interview with Biospace.com, the most comprehensive Life Science industry news and information source
Martin Tolar, chief executive officer of Framingham, Mass. based Alzheon, told BioSpace that his company’s drug was designed to inhibit the formation of toxic soluble amyloid oligomers. It’s the oligomers that are the key driver of Alzheimer’s disease. Data collected by the company shows that if you target the oligomers, there is a chance to arrest the disease, Tolar said.
Read the full article here